Variations in tissue selectivity amongst insulin secretagogues: A systematic review

Diabetes, Obesity and Metabolism

Volumn 14, Issue 2, 2012, Pages 130-138

  Abdelmoneim, A S ^a   Hasenbank, S E ^a   Seubert, J M ^a   Brocks, D R ^a   Light, P E ^a   Simpson, S H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Insulin secretagogues; Ischaemic preconditioning; Sulfonylurea receptor

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLICLAZIDE; GLIPIZIDE; HEART RECEPTOR; INSULIN RECEPTOR; MITIGLINIDE; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 1; SULFONYLUREA RECEPTOR 2; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; DRUG BINDING SITE; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HUMAN; IC 50; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; STEADY STATE; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 84855344282     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01496.x     Document Type: Article

References (85)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32(Suppl. 1): S1-201.
2. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 2009; 32: 193-203.
3. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 168: 2088-2094.
4. Canadian Agency for Drugs and Technologies in Health. Current Utilization of Second- and Third-Line Therapies in Patients with Type 2 Diabetes. 2010; 4: 1-33.
5. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Progress in biophysics and molecular biology 1989; 54: 87-143.
6. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003; 46: 875-891.
7. Nichols CG, Lederer WJ. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol 1991; 261(6 Pt 2): H1675-H1686.
8. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997; 77: 1165-1232.
9. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
10. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 2007; 292: H19-H27.
11. Muller DW, Topol EJ, Califf RM et al. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1990; 119(2 Pt 1): 224-231.
12. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
13. Suzuki M, Sasaki N, Miki T et al. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 2002; 109: 509-516.
14. Yudkin JS, Oswald GA. Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care 1988; 11: 351-358.
15. Pogatsa G, Koltai MZ, Jermendy G, Simon J, Aranyi Z, Ballagi-Pordany G. The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients. Acta Med Hung 1992; 49: 39-51.
16. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.
17. Jollis JG, Simpson RJ Jr, Cascio WE, Chowdhury MK, Crouse Jr, III, Smith SC Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138(5 Pt 1): S376-S380.
18. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21: 220-229.
19. Halkin A, Roth A, Jonas M, Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001; 12: 177-184.
20. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
21. McGuire DK, Newby LK, Bhapkar MV et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004; 147: 246-252.
22. Danchin N, Charpentier G, Ledru F et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005; 21: 143-149.
23. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med 2005; 22: 497-502.
24. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
25. Horsdal HT, Johnsen SP, Sondergaard F, Rungby J. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008; 51: 567-574.
26. Lang V, Light PE. The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. Pharmacogen Pers Med 2008; 2010: 145-161.
27. Winkler M, Stephan D, Bieger S, Kuhner P, Wolff F, Quast U. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands. J Pharmacol Exp Ther 2007; 322: 701-708.
28. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51(Suppl. 3): S368-376.
29. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9-12.
30. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complicat 2003; 17(Suppl. 2): 11-15.
31. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complicat 2000; 14: 192-196.
32. Collaboration Centre for Drug Statistics Methodology. ATC/DDD Index WHO 2011.
33. Kobayashi KA, Bauer LA, Horn JR, Opheim K, Wood F Jr, Kradjan WA. Glipizide pharmacokinetics in young and elderly volunteers. Clin Pharm 1988; 7: 224-228.
34. Gross AS, Bridge S, Shenfield GM. Pharmacokinetics of tolbutamide in ethnic Chinese. Br J Clin Pharmacol 1999; 47: 151-156.
35. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41: 471-483.
36. Weaver ML, Orwig BA, Rodriguez LC et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 2001; 29(4 Pt 1): 415-421.
37. Zhang Y, Ding L, Tian Y, Yang J, Yang L, Wen A. Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies. Biomed Chromatogr 22: 873-878.
38. Kubacka RT, Antal EJ, Juhl RP. The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1987; 23: 743-751.
39. Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 2004; 38: 30-35.
40. Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 2003; 74: 334-340.
41. Babenko AP, Gonzalez G, Aguilar-Bryan L, Bryan J. Reconstituted human cardiac KATP channels: functional identity with the native channels from the sarcolemma of human ventricular cells. Circ Res 1998; 83: 1132-1143.
42. Barrett-Jolley R, Davies NW. Kinetic analysis of the inhibitory effect of glibenclamide on KATP channels of mammalian skeletal muscle. J Membr Biol 1997; 155: 257-262.
43. Chachin M, Yamada M, Fujita A, Matsuoka T, Matsushita K, Kurachi Y. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels. J Pharmacol Exp Ther 2003; 304: 1025-1032.
44. Dabrowski M, Wahl P, Holmes WE, Ashcroft FM. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001; 44: 747-756.
45. Dorschner H, Brekardin E, Uhde I, Schwanstecher C, Schwanstecher M. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol Pharmacol 1999; 55: 1060-1066.
46. Findlay I. Effects of pH upon the inhibition by sulphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle. J Pharmacol Exp Ther 1992; 262: 71-79.
47. Giblin JP, Leaney JL, Tinker A. The molecular assembly of ATP-sensitive potassium channels. Determinants on the pore forming subunit. J Biol Chem 1999; 274: 22652-22659.
48. Gopalakrishnan M, Molinari EJ, Shieh CC et al. Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. Br J Pharmacol 2000; 129: 1323-1332.
49. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 1998; 47: 1412-1418.
50. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 1999; 42: 845-848.
51. Gribble FM, Tucker SJ, Ashcroft FM. The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation. J Physiol 1997; 504(Pt 1): 35-45.
52. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-1032.
53. Hambrock A, Loffler-Walz C, Russ U, Lange U, Quast U. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes. Mol Pharmacol 2001; 60: 190-199.
54. Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 2002; 51: 2789-2795.
55. Hu S, Wang S, Dunning BE. Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels. J Pharmacol Exp Ther 1999; 291: 1372-1379.
56. Hu S. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. Eur J Pharmacol 2002; 442: 163-171.
57. Lawrence CL, Rainbow RD, Davies NW, Standen NB. Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels. Br J Pharmacol 2002; 136: 746-752.
58. Lawrence CL, Proks P, Rodrigo GC et al. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia 2001; 44: 1019-1025.
59. Manning Fox JE, Kanji HD, French RJ, Light PE. Cardioselectivity of the sulphonylurea HMR 1098: studies on native and recombinant cardiac and pancreatic K(ATP) channels. Br J Pharmacol 2002; 135: 480-488.
60. Proks P, Treinies I, Mest HJ, Trapp S. Inhibition of recombinant K(ATP) channels by the antidiabetic agents midaglizole, LY397364 and LY389382. Eur J Pharmacol 2002; 452: 11-19.
61. Reimann F, Dabrowski M, Jones P, Gribble FM, Ashcroft FM. Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol 2003; 547(Pt 1): 159-168.
62. Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol 2001; 132: 1542-1548.
63. Russ U, Lange U, Loffler-Walz C, Hambrock A, Quast U. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP-sensitive K(+) channels: comparison with glibenclamide. J Pharmacol Exp Ther 2001; 299: 1049-1055.
64. Schwanstecher M, Mnner K, Panten U. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets. Pharmacology 1994; 49: 105-111.
65. Sunaga Y, Gonoi T, Shibasaki T et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 2001; 431: 119-125.
66. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol 2001; 133: 193-199.
67. Stephan D, Winkler M, Kuhner P, Russ U, Quast U. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. Diabetologia 2006; 49: 2039-2048.
68. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29: 207-222.
69. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004; 18: 113-119.
70. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19(Suppl. 2): 789-830.
71. Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 1998; 97: 709-710.
72. Azoulay L, Schneider-Lindner V, Dell'aniello S, Schiffrin A, Suissa S. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 335-342.
73. Horsdal HT, Sondergaard F, Johnsen SP, Rungby J. Antdiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Saf 2011; 20: 331-337.
74. Ohneda A, Maruhama Y, Itabashi H et al. Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus. Tohoku J Exp Med 1978; 124: 205-222.
75. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 1998; 21: 637-640.
76. Johnsen SP, Monster TB, Olsen ML et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006; 13: 134-140.
77. Monami M, Balzi D, Lamanna C et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; 23: 479-484.
78. Evans JM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes, Obes Metab 2008; 10: 350-352.
79. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009; 86: 247-253.
80. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900-1908.
81. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
82. Brocks DR, Jamali F. Enantioselective pharmacokinetics of etodolac in the rat: tissue distribution, tissue binding, and in vitro metabolism. J Pharm Sci 1991; 80: 1058-1061.
83. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111-3116.
84. Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care 1998; 21: 487-493.
85. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006; 53: 87-94.